Scarica l'app Stockscreener
97.46
4.07%
-4.13
Dopo l'orario di chiusura:
97.46
Precedente Chiudi:
$101.59
Aprire:
$100
Volume 24 ore:
593.46K
Relative Volume:
0.80
Capitalizzazione di mercato:
$6.50B
Reddito:
$136.86M
Utile/perdita netta:
$-168.69M
Rapporto P/E:
-34.68
EPS:
-2.81
Flusso di cassa netto:
$-113.49M
1 W Prestazione:
-8.95%
1M Prestazione:
-7.34%
6M Prestazione:
+49.62%
1 anno Prestazione:
+68.41%
Intervallo 1D:
$96.20
$100.46
Intervallo di 1 settimana:
$96.20
$108.17
Portata 52W:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Confronta RYTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
97.46 | 6.78B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Iniziato | Citigroup | Buy |
| 2025-11-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-07-07 | Iniziato | Leerink Partners | Outperform |
| 2025-04-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2025-01-02 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Guggenheim | Buy |
| 2024-09-18 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Reiterato | Needham | Buy |
| 2022-03-02 | Ripresa | Stifel | Buy |
| 2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Ripresa | Goldman | Neutral |
| 2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-01-08 | Iniziato | Goldman | Sell |
| 2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2019-07-08 | Iniziato | Canaccord Genuity | Buy |
| 2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-09-07 | Ripresa | Morgan Stanley | Overweight |
| 2018-06-25 | Reiterato | Needham | Buy |
| 2018-06-15 | Reiterato | Needham | Buy |
| 2017-10-30 | Iniziato | BofA/Merrill | Buy |
| 2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
How cyclical is Rhythm Pharmaceuticals Inc. (1RV) stock compared to rivalsJuly 2025 Reactions & High Win Rate Trade Tips - ulpravda.ru
How Rhythm Pharmaceuticals Inc. stock reacts to oil prices2025 Fundamental Recap & Community Verified Trade Alerts - ulpravda.ru
CEO Moves: Why Rhythm Pharmaceuticals Inc. (1RV) stock fits value portfolios2025 Biggest Moves & Advanced Swing Trade Entry Alerts - ulpravda.ru
Rhythm Pharmaceuticals, Inc. (RYTM): Analyst Consensus and Growth Potential Amidst a 32% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates - MSN
Understanding the Setup: (RYTM) and Scalable Risk - Stock Traders Daily
Is Rhythm Pharmaceuticals Inc a good long term investmentEconomic Indicators Overview & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
What Technical Indicators Signal for BLS E Next MonthCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling - FinancialContent
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus - ts2.tech
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 3.3%Should You Sell? - MarketBeat
Rhythm Pharmaceuticals Earnings Notes - Trefis
Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome - MSN
Rhythm Pharma’s Rare-Obesity Drug Keeps Growth Rolling - Finimize
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rhythm Pharmaceuticals (RYTM) Stock Analysis: Exploring a 26% Upside Potential in Biotech - DirectorsTalk Interviews
Does Rhythm Pharmaceuticals (NASDAQ:RYTM) Have A Healthy Balance Sheet? - 富途牛牛
Harbor Capital Advisors Inc. Has $3.76 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (FRA:1RV) OCF Margin % : -51.90% (As of Sep. 2025) - GuruFocus
Rhythm Pharmaceuticals (FRA:1RV) EV-to-FCF : -62.60 (As of Dec. 25, 2025) - GuruFocus
Rhythm Pharmaceuticals (FRA:1RV) EV-to-OCF : -62.60 (As of Dec. 25, 2025) - GuruFocus
Why (RYTM) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on PWS trial data - Investing.com Canada
RYTM: HC Wainwright Raises Price Target for Rhythm Pharmaceutica - GuruFocus
Voya Investment Management LLC Has $22.38 Million Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
HC Wainwright & Co. Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
With Rhythm Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
What is the fair value estimate for Rhythm Pharmaceuticals Inc. (1RV) stock in 2025Earnings Growth Summary & Weekly High Return Stock Opportunities - Улправда
How Rhythm Pharmaceuticals Inc. stock performs in weak economy2025 Major Catalysts & Safe Capital Allocation Plans - Улправда
Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
How institutional buying supports Rhythm Pharmaceuticals Inc. stockWeekly Trade Report & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Is Rhythm Pharmaceuticals Inc. (1RV) stock a top dividend aristocrat candidateJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - Улправда
Shorts Report: Is Rhythm Pharmaceuticals Inc. (1RV) stock a top dividend aristocrat candidate2025 Technical Patterns & Daily Growth Stock Tips - Улправда
Can Rhythm Pharmaceuticals Inc. stock reach $100 price targetRecession Risk & Fast Exit Strategy with Risk Control - ulpravda.ru
How Rhythm Pharmaceuticals Inc. stock performs in rate cut cycles2025 Price Targets & High Win Rate Trade Alerts - Улправда
Guggenheim Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next StepsSlideshow (NASDAQ:RYTM) 2025-12-17 - Seeking Alpha
Guggenheim Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $140 | RYTM Stock News - GuruFocus
Pamela Cramer Sells 3,350 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock - MarketBeat
Rhythm Pharmaceuticals Executive Sells Shares - TradingView — Track All Markets
FDA Action Alert: GSK, Aldeyra, Rhythm and More - BioSpace
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Rhythm Pharmaceuticals (RYTM) - The Globe and Mail
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $167.00 at Citizens Jmp - MarketBeat
Rhythm Pharmaceuticals stock rises after positive study data for setmelanotide in treating genetic disorder - MSN
Alkeon Capital Management LLC Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Citizens Maintains Rhythm Pharmaceuticals (RYTM) Market Outperform Recommendation - Nasdaq
Canaccord Genuity Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
RYTM Stock: Canaccord Genuity Raises Price Target to $141, Maint - GuruFocus
Goldman Sachs Raises Price Target for RYTM to $157, Maintains Bu - GuruFocus
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):